FR2873294B1 - Association de medicaments - Google Patents

Association de medicaments

Info

Publication number
FR2873294B1
FR2873294B1 FR0408257A FR0408257A FR2873294B1 FR 2873294 B1 FR2873294 B1 FR 2873294B1 FR 0408257 A FR0408257 A FR 0408257A FR 0408257 A FR0408257 A FR 0408257A FR 2873294 B1 FR2873294 B1 FR 2873294B1
Authority
FR
France
Prior art keywords
drugs
association
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0408257A
Other languages
English (en)
Other versions
FR2873294A1 (fr
Inventor
Philippe Bernard
Fabrice Trovero
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Greenpharma SAS
Original Assignee
Greenpharma SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0408257A priority Critical patent/FR2873294B1/fr
Application filed by Greenpharma SAS filed Critical Greenpharma SAS
Priority to US11/658,643 priority patent/US20080194631A1/en
Priority to CA002575848A priority patent/CA2575848A1/fr
Priority to JP2007523117A priority patent/JP2008507577A/ja
Priority to PCT/FR2005/001942 priority patent/WO2006018538A1/fr
Priority to EP05793762A priority patent/EP1773306A1/fr
Priority to CNA2005800293340A priority patent/CN101014325A/zh
Publication of FR2873294A1 publication Critical patent/FR2873294A1/fr
Application granted granted Critical
Publication of FR2873294B1 publication Critical patent/FR2873294B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR0408257A 2004-07-26 2004-07-26 Association de medicaments Expired - Lifetime FR2873294B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR0408257A FR2873294B1 (fr) 2004-07-26 2004-07-26 Association de medicaments
CA002575848A CA2575848A1 (fr) 2004-07-26 2005-07-26 Medicament destine au traitement des desordres du systeme nerveux central
JP2007523117A JP2008507577A (ja) 2004-07-26 2005-07-26 中枢神経系の障害を治療するための医薬
PCT/FR2005/001942 WO2006018538A1 (fr) 2004-07-26 2005-07-26 Medicament destine au traitement des desordres du systeme nerveux central
US11/658,643 US20080194631A1 (en) 2004-07-26 2005-07-26 Medicament For the Treatment of Central Nervous System Disorders
EP05793762A EP1773306A1 (fr) 2004-07-26 2005-07-26 Medicament destine au traitement des desordres du systeme nerveux central
CNA2005800293340A CN101014325A (zh) 2004-07-26 2005-07-26 治疗中枢神经系统病症的药物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0408257A FR2873294B1 (fr) 2004-07-26 2004-07-26 Association de medicaments

Publications (2)

Publication Number Publication Date
FR2873294A1 FR2873294A1 (fr) 2006-01-27
FR2873294B1 true FR2873294B1 (fr) 2008-05-09

Family

ID=34950699

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0408257A Expired - Lifetime FR2873294B1 (fr) 2004-07-26 2004-07-26 Association de medicaments

Country Status (7)

Country Link
US (1) US20080194631A1 (fr)
EP (1) EP1773306A1 (fr)
JP (1) JP2008507577A (fr)
CN (1) CN101014325A (fr)
CA (1) CA2575848A1 (fr)
FR (1) FR2873294B1 (fr)
WO (1) WO2006018538A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2206781B1 (fr) 2004-06-28 2015-12-02 The University Of Western Australia Oligonucléotides antisens permettant d'induire un saut d'exon et leurs procédés d'utilisation
WO2009058261A1 (fr) * 2007-10-31 2009-05-07 Merck & Co., Inc. Modulation du sommeil avec des antagonistes du récepteur nr2b
DK3106166T3 (da) 2008-02-29 2021-01-11 Vm Therapeutics Llc Forbindelser til behandling af smertesyndrom og andre lidelser
ES2693459T3 (es) 2009-11-12 2018-12-11 The University Of Western Australia Moléculas antisentido y métodos para el tratamiento de patologías
FR2954699B1 (fr) * 2009-12-30 2012-01-20 Greenpharma Sas Composition pharmaceutique pour le traitement de la dependance a l'alcool
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US10583138B2 (en) 2012-07-12 2020-03-10 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
FR2976807B1 (fr) 2011-06-24 2013-07-05 Greenpharma Sas Composition pharmaceutique pour le traitement de la dependance chez l'etre humain
EP3633035A1 (fr) 2013-03-14 2020-04-08 Sarepta Therapeutics, Inc. Compositions de saut d'exons pour le traitement de la dystrophie musculaire
KR101858055B1 (ko) * 2015-08-04 2018-05-15 아스테라스 세이야쿠 가부시키가이샤 탐스로신을 유효성분으로 포함하는 인지기능 개선용 조성물
US11103499B2 (en) * 2016-08-26 2021-08-31 EXCIVA (UG) (haftungsbeschränkt) Compositions and methods thereof
KR20200046525A (ko) * 2018-10-24 2020-05-07 건국대학교 글로컬산학협력단 피렌페론 화합물을 유효성분으로 포함하는 취약 x 증후군 및 관련 발달 장애치료용 조성물
CN115844898A (zh) * 2022-12-02 2023-03-28 浙江工业大学 布那唑嗪在制备预防或治疗酒精使用障碍的药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL87710A (en) * 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
CN1210726A (zh) * 1997-09-08 1999-03-17 郑万伦 一种快速脱毒的戒毒药品
EP1430890A4 (fr) * 2001-09-26 2007-01-17 Mitsubishi Pharma Corp Inhibiteurs de thrombus/thrombogenese

Also Published As

Publication number Publication date
CN101014325A (zh) 2007-08-08
JP2008507577A (ja) 2008-03-13
WO2006018538A1 (fr) 2006-02-23
FR2873294A1 (fr) 2006-01-27
US20080194631A1 (en) 2008-08-14
EP1773306A1 (fr) 2007-04-18
CA2575848A1 (fr) 2006-02-23

Similar Documents

Publication Publication Date Title
FR2867064B1 (fr) Doseur de medicaments
DE602005026188D1 (de) Medikamentenspender
CY2017048I1 (el) Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης
PT1957073E (pt) Medicamento
DK2073795T3 (da) Misbrugssikret lægemiddelformulation
CY2018005I2 (el) Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης
MA28489B1 (fr) Preparations pharmaceutiques
BRPI0511900A (pt) composições farmacêuticas
DK2399580T3 (da) Farmaceutiske doseringsformer
DK1757293T3 (da) Bh4-responsiv hyperphenylalaninæmi-medikamenter
FR2873294B1 (fr) Association de medicaments
DE602005017643D1 (de) Medikamentenverdunster
ITMI20041447A1 (it) Composizione farmaceutica comprendente gabapentina
NO20034952D0 (no) Farmasöytiske forbindelser
ITMI20040943A1 (it) Composizione farmaceutica cicatrizzante
ITRM20030053A1 (it) Associazione di farmaci antidiabetici.
DE112004001429D2 (de) Pharmazeutischer Wirkstoff
SE0400990D0 (sv) Läkemedel
FI20040558A0 (fi) Farmaseuttinen valmiste
UA10054S (uk) Упаковка фармацевтичного засобу
UA10038S (uk) Упаковка фармацевтичного засобу
UA10535S (uk) Упаковка фармацевтичного засобу
UA10843S (uk) Упаковка фармацевтичного засобу
UA10842S (uk) Піктограма фармацевтичного засобу
UA10644S (uk) Піктограма фармацевтичного засобу

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20